# Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

> **NCT07753148** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 52 (estimated)

## Conditions studied

- Clonal Cytopenia of Undetermined Significance (CCUS)
- Low-Risk Myelodysplastic Syndrome (LR-MDS)

## Interventions

- **DRUG:** REGN17235

## Key facts

- **NCT ID:** NCT07753148
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2031-05-05
- **Final completion:** 2031-05-05
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753148, "Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07753148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*